Three new cephalosporins, ceftazidime, ceftizoxime, and cefotiam, were evaluated in vitro against clinical isolates, and their activities were compared with those of other cephalosporins, mezlocillin, and tobramycin. All three new cephalosporins were very active against gram-positive cocci (except enterococci), but mezlocillin was more active against Streptococcus spp. Cefotiam and cefamandole were the most active antibiotics against Staphylococcus aureus. Ceftazidime had broad-spectrum activity against all gram-negative bacilli tested, except Enterobacter spp. Ceftizoxime was active against all, except Enterobacter spp. and Pseudomonas aeruginosa. Although cefotiam was quite active against Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis, it was inactive against indole-positive Proteus spp., Enterobacter spp., Serratia spp., and P. aeruginosa. The in vitro activity suggests that ceftazidime should prove useful as a broadspectrum antibiotic, in those settings in which the most likely pathogens are gram-negative bacilli.
Numerous cephalosporin derivatives have been synthesized since the introduction of cephalothin into clinical practice more than a decade ago. The earliest analogs offered only modest advantages over cephalothin, such as greater in vitro activity against the same spectrum of organisms, oral absorption, or superior pharmacokinetics. The "second-generation" cephalosporins, such as cefamandole and cefoxitin, broadened the spectrum of activity to include some isolates of Serratia spp. and Enterobacter and cephalothin-resistant anaerobes (1, 2) . More recently, a group of "third-generation" cephalosporins have been synthesized. These are truly broad-spectrum antibiotics with activity against most Enterobacteriaceae and some Pseudomonas aerugu8osa (3, 4, (7) (8) (9) (10) .
Ceftazidime (GR-20263) and ceftizoxime (FK-749) are new third-generation cephalosporins which have recently become available for in vitro evaluation. Cefotiam (SCE-963) is a new second-generation cephalosporin. The present study was undertaken to evaluate and compare the activity of these new cephalosporins with one another and with cefoperazone, moxalactam, cefoxitin, cefamandole, mezlocillin, and tobramycin. The majority of isolates evaluated in this study caused bacteremia in cancer patients. Hence, the results provide an estimate of the potential usefulness of these agents in patients with compromised host defense mechanisms. Susceptibility testing. All isolates were tested in Mueller-Hinton broth, with the exception of isolates of S. pyogenes and S. pneumoniae, which were tested in tryptose-phosphate broth. For the comparative studies of the nine antibiotics, the plates were inoculated automatically. A Dynatech MIC 2000 inoculator delivered 0.0015 ml of a 1:10 dilution of broth cultures incubated at 370C for 18 h into wells holding 0.10 ml of media containing various antibiotic dilutions. For studies of the effects of human serum and inoculum variation, the plates were inoculated manually. A 0.05-ml sample of a 1:1,000 dilution of broth cultures incubated at 37°C for 18 h was inoculated into wells holding 0.05 ml of media containing various antibiotic dilutions. Enterobacter cloacae ATCC 13047, Proteus vulgaris ATCC 6380, and K. pneumoniae ATCC 27736 were included as controls during each procedure.
MATERIALS AND METHODS
The effect of inoculum size was determined with concentrations of 102, 104, 106, and 108 cells per ml.
The same 10 strains each of E. coli, Klebsiella spp., Enterobacter spp., and P. aeruginosa were used for these studies with ceftazidime, ceftizoxime, and cefotiam.
Definitions. The miniimal inhibitory concentration (MIC) was defined as the lowest concentration of drug which suppressed visible growth after incubation at 370C for 18 h for gram-negative bacilli and isolates of S. aureus and after incubation at 37°C in a C02
incubator for 24 h for isolates of S. pyogenes and S. pneumoniae. The miniimal bactericidal concentration (MBC) was defined as the lowest concentration of drug which yielded less than five colonies on subculture to sheep blood agar (99.5% killed) after incubation at 370C for 18 h. A micropipetting device was used to deliver 10 A1 for subculture. MBC determinations were performed only for ceftazidime, ceftizoxime, and cefotiam.
RESULTS
The in vitro activity of the cephalosporins and mezlocillin against gram-positive cocci is recorded in Table 1 . Tobramycin was not tested against these organisms. Ceftizoxime and mezlocillin were the most active antibiotics against S. pyogenes. Moxalactam and cefoxitin were the least active, although all of the isolates were susceptible to concentrations of 3.12 ,ug or less of these antibiotics per ml. Interestingly, the three new cephalosporins were bactericidal against less than 10% of these isolates at the MIC. The MBC for ceftazidime and cefotiam against 90% of the isolates was 3.12 ,tg/ml. The 
